FLIP Antibody [Dave-2] | XA-1008

FLIP Antibody [Dave-2] | XA-1008 | Gentaur UK, US & Europe Distribution

Host: Rat

Reactivity: Human, Mouse

Homology: N/A

Immunogen: Recombinant human FLIP (aa 1-480) .

Research Area: Apoptosis, Cancer

Tested Application: IP, WB

Application: Immunoprecipitation: (1-2ug/ml) . Western Blot: (1-5ug/ml) . Optimal conditions must be determined individually for each application.

Specificiy: Recognizes an epitope (aa 1-200) present in both short (FLIPS) and long (FLIPL) splice variants of human and mouse FLIP.

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: N/A

Clonality: Monoclonal

Clone: Dave-2

Isotype: IgG2a

Conjugate: Unconjugated

Physical State: Liquid

Buffer: Liquid. In PBS containing 10% glycerol and 0.02% sodium azide.

Concentration: 1 mg/ml

Storage Condition: Stable for at least 1 year after receipt when stored at -20˚C.

Alternate Name: I-FLICE; CLARP; CASPER; Usurpin, CASH; FLAME-1

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: FLIP is an apoptosis regulator protein which functions as a crucial link between cell survival and cell death pathways in mammalian cells and acts as an inhibitor of TNFRSF6 mediated apoptosis. A proteolytic fragment (p43) is likely retained in the death-inducing signaling complex (DISC) thereby blocking further recruitment and processing of caspase-8 at the complex. Full length and shorter isoforms have been shown either to induce apoptosis or to reduce TNFRSF-triggered apoptosis. FLIP lacks enzymatic (caspase) activity. FLIP is highly expressed in skeletal muscle, pancreas, heart, kidney, placenta and peripheral blood leukocytes.